Radiation Oncology/Therapy: Page 32

FDA clears Radialis PET imager

By AuntMinnie.com staff writers

The U.S. Food and Drug Administration (FDA) has cleared Radialis' PET Imager, a small footprint, organ-targeted device.

July 17, 2022

ECR: Should patient radiation shielding stay or should it go?

By Will Morton

European experts are gradually reaching a consensus that radiation shielding is no longer needed for some imaging exams, yet the idea may be a hard pill to swallow at some facilities. With that in mind, a panel discussion held at ECR 2022 in Vienna addressed the pros and cons of the issue.

July 17, 2022

Accuray highlights data presented at ISRS 2022

By AuntMinnie.com staff writers

Radiation therapy developer Accuray is highlighting research being presented at the International Stereotactic Radiosurgery Society (ISRS) meeting in Milan, Italy, that the company says demonstrates the value of its CyberKnife system for treating neurological indications.

July 12, 2022

RaySearch tech to be used in Houston clinic

By AuntMinnie.com staff writers

RaySearch Laboratories said the company's RayStation has been selected by Harris Health System in Texas for its Smith Clinic location.

July 7, 2022

RefleXion and Mirada ink software licensing deal

By AuntMinnie.com staff writers

RefleXion Medical and Mirada Medical have established a licensing agreement to integrate Mirada's RegEngine image registration software into the RefleXion X1 radiation therapy system.

July 6, 2022

DWI-MRI predicts whether women's DCIS will upstage after surgery

By Kate Madden Yee

Preoperative diffusion-weighted MRI (DWI-MRI) is effective for predicting whether biopsy-confirmed ductal carcinoma in situ (DCIS) will be reclassified as invasive cancer after surgery, a study published July 5 in Radiology has found.

July 6, 2022

RefleXion closes $125M debt facility

By AuntMinnie.com staff writers

Radiation therapy equipment developer RefleXion Medical announced the closing of a $125 million debt facility.

July 5, 2022

PSMA-PET/CT comparable to MRI for detecting prostate cancer

By Kate Madden Yee

Prostate-specific membrane antigen (PSMA)-PET/CT imaging is comparable to MRI for detecting clinically significant prostate cancer. But MRI is still the more accurate modality for detecting the grade of disease, according to research presented on July 3 at the European Association of Urology in Amsterdam, the Netherlands.

July 5, 2022

IBA forms ConformalFlash alliance

By AuntMinnie.com staff writers

Proton therapy developer Ion Beam Applications (IBA) has launched the ConformalFlash Alliance, a new collaboration between companies and academia to facilitate clinical adoption of the firm's ConformalFlash technology.

July 4, 2022

Novartis restarts supply of Lutathera and Pluvicto

By AuntMinnie.com staff writers

Novartis has taken steps to resolve quality issues that halted production of its Lu-177 DOTATATE (Lutathera) and Lu-177-PSMA-617 (Pluvicto) radiopharmaceutical cancer therapies, yet the dip in supply is still affecting patients, their families, and care teams.

June 30, 2022

RaySearch launches latest version of RayStation

By AuntMinnie.com staff writers

RaySearch Laboratories has launched RayStation 12A, the latest version of the company’s treatment planning software.

June 30, 2022

ASTRO recognizes fellows class for 2022

By AuntMinnie.com staff writers

The American Society for Radiation Oncology (ASTRO) recently named 27 distinguished members for the ASTRO Fellow (FASTRO) designation.

June 30, 2022

Previous Page

Page 32 of 468

Next Page